Bias (Epidemiology) < Binding Sites < Binding, Competitive

Facettes :

List of bibliographic references indexed by Binding Sites

Number of relevant bibliographic references: 22.
[0-20] [0 - 20][0 - 22][20-21][20-40]

Ident.	Authors (with country if any)	Title
000139 (2016)	Tarek Ibrahim [Canada] ; Joanne Mclaurin [Canada]	α-Synuclein aggregation, seeding and inhibition by scyllo-inositol.
000760 (2015)	Atul Kumar [Royaume-Uni] ; Jacob D. Aguirre [Canada] ; Tara E C. Condos [Canada] ; R Julio Martinez-Torres [Royaume-Uni] ; Viduth K. Chaugule [Royaume-Uni] ; Rachel Toth [Royaume-Uni] ; Ramasubramanian Sundaramoorthy [Royaume-Uni] ; Pascal Mercier [Canada] ; Axel Knebel [Royaume-Uni] ; Donald E. Spratt [Canada] ; Kathryn R. Barber [Canada] ; Gary S. Shaw [Canada] ; Helen Walden [Canada]	Disruption of the autoinhibited state primes the E3 ligase parkin for activation and catalysis.
000888 (2014)	Omid Tavassoly [Canada] ; Joe Kakish [Canada] ; Sergiy Nokhrin [Canada] ; Oleg Dmitriev [Canada] ; Jeremy S. Lee [Canada]	The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease.
000B13 (2014)	Omid Tavassoly [Canada] ; Sergiy Nokhrin ; Oleg Y. Dmitriev ; Jeremy S. Lee	Cu(II) and dopamine bind to α-synuclein and cause large conformational changes.
001180 (2012)	Hongyan Song [Canada] ; John Parkinson	Modelling the self-assembly of elastomeric proteins provides insights into the evolution of their domain architectures.
001185 (2012)	Omid Tavassoly [Canada] ; Jeremy S. Lee	Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
001A48 (2010)	Shuye Pu [Canada] ; Andrei L. Turinsky ; James Vlasblom ; Tuan On ; Xuejian Xiong ; Andrew Emili ; Zhaolei Zhang ; Jack Greenblatt ; John Parkinson ; Shoshana J. Wodak	Expanding the landscape of chromatin modification (CM)-related functional domains and genes in human.
001B00 (2010)	Zhou Yu [Canada] ; Sean E. Reichheld ; Alexei Savchenko ; John Parkinson ; Alan R. Davidson	A comprehensive analysis of structural and sequence conservation in the TetR family transcriptional regulators.
002463 (2007)	Haoran Wang [Canada] ; Mary X. Gao ; Linda Li ; Bin Wang ; Naohiro Hori ; Kenzo Sato	Isolation, expression, and characterization of the human ZCRB1 gene mapped to 12q12.
002480 (2007)	Andis Klegeris [Canada] ; Patrick L. Mcgeer	Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112.
002987 (2005)	Dominic Cuerrier [Canada] ; Tudor Moldoveanu ; Peter L. Davies	Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions.
002D61 (2003)	Doris J. Doudet [Canada] ; James E. Holden	Raclopride studies of dopamine release: dependence on presynaptic integrity.
002D75 (2003)	Frédéric Calon [Canada] ; Ali H. Rajput ; Oleh Hornykiewicz ; Paul J. Bédard ; Thérèse Di Paolo	Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
003367 (2000)	M. Aschner [États-Unis]	Manganese: brain transport and emerging research needs.
003545 (2000)	Frédéric Calon ; Marc Morissette ; Martin Goulet ; Richard Grondin ; Pierre J. Blanchet ; Paul J. Bédard ; Thérèse Di Paolo	125I-CGP 64213 Binding to GABAB Receptors in the Brain of Monkeys: Effect of MPTP and Dopaminomimetic Treatments
003562 (2000)	M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]	Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys
003D22 (1996)	Fiona E. Parkinson [Canada] ; Kallol Mukherjee [Canada] ; Jonathan D. Geiger [Canada]	[3H]Adenosine transport in DDT1 MF-2 smooth muscle cells: inhibition by metabolites of propentofylline
004081 (1995)	H. Shinotoh [Canada] ; D. B. Calne	The use of PET in Parkinson's disease
004461 (1993)	A. P. Sen [Canada] ; P. Boksa ; R. Quirion	Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer's, Parkinson's and Huntington's diseases
004656 (1992)	I. Aubert [Canada] ; D. M. Araujo ; D. Cecyre ; Y. Robitaille ; S. Gauthier ; R. Quirion	Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases
004813 (1991)	H. B. Niznik ; E. F. Fogel ; F. F. Fassos ; P. Seeman	The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Binding Sites" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Binding Sites" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Binding Sites
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022